CGRP Signaling Blockade for NEHI Pulmonary Edema
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is no specific therapeutic approach for Neuroendocrine Hyperplasia of Infancy (NEHI), a rare childhood lung disease characterized by gas-exchange deficiency and pulmonary edema, with increased pulmonary neuroendocrine cells (PNECs) contributing to symptoms, and existing treatments are mainly supportive.
Innovation Solution
Development of a mouse model with a NKX2-1 gene mutation to replicate NEHI, demonstrating that excessive PNEC products like CGRP disrupt endothelial integrity, leading to pulmonary edema, and treatment with CGRP signaling inhibitors or antagonists to alleviate these symptoms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PNECs secrete bioactive neuropeptides and neurotransmitters in response to aerosol stimuli, then immune cell recruitment and goblet cell metaplasia are facilitated, but pulmonary edema and gas-exchange deficiency occur
Solution Approach 1:
The patent extracts and removes the harmful substance (CGRP) from the system using neutralizing antibodies or CGRP receptor antagonists. This selectively eliminates the harmful effect of excessive CGRP secretion while preserving the essential functions of PNECs in immune response and airway regulation.
Solution Approach 2:
The patent introduces intermediary substances (monoclonal antibodies against CGRP or CGRP receptor antagonists) that mediate between the excessive CGRP secretion and its harmful effects. These intermediaries bind to CGRP or block its receptors, preventing the harmful downstream effects while allowing physiological levels of CGRP to function normally.
2Quantity of substance
If NKX2-1 gene mutation occurs, then PNEC hyperplasia develops, but endothelial integrity is disrupted and pulmonary edema results
Solution Approach 1:
The patent converts the harmful effect of PNEC hyperplasia and excessive CGRP secretion into a beneficial treatment opportunity. By using monoclonal antibodies or CGRP antagonists, the excessive CGRP signaling is blocked, transforming the pathological condition into a treatable state that restores endothelial integrity and resolves pulmonary edema.
Solution Approach 2:
The patent changes the parameter of CGRP signaling activity from excessive (pathological) to appropriate (physiological) levels. Through pharmacological intervention with CGRP antagonists or neutralizing antibodies, the signaling parameter is adjusted to restore normal endothelial function and eliminate pulmonary edema while maintaining PNEC hyperplasia.
3Reliability
If supportive treatment with supplemental oxygen is provided, then gas-exchange deficiency is managed, but no disease-specific treatment is available
Solution Approach 1:
The patent develops a disease-specific treatment mechanism (CGRP neutralization) that can be applied to NEHI and potentially other conditions involving excessive CGRP signaling. The monoclonal antibodies and CGRP antagonists provide a universal therapeutic approach that addresses the root cause (excessive CGRP) rather than just managing symptoms, enabling both specific and broad applicability.
Data Source
AI summary
The present disclosure provides a novel animal model of NEHI, and method of preventing and/or treating a pulmonary disease, particularly the lung-based complications in NEHI, such as pulmonary edema, by targeting the PNEC product, such as the CGRP signaling. Also disclosed is the pharmaceutical composition for preventing and/or treating a pulmonary edema and/or other pulmonary disease, particularly, NEHI, comprising one or more CGRP signaling antagonist and/or inhibitor of the present disclosure.